Ireland
--:--IST
Priya Life Science Clinical trial register
Trackers› Clinical trials› B Cell Lymphoma
Clinical trial register · China

B Cell Lymphoma Trials in China, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 19187 matching records held by the registry are in this view. Synced 09 Nov 2026, 03:17 UTC
19187
Studies in scope
all four open statuses
11790
Recruiting now
open to new participants
2028
Lead sponsors
across recruiting studies
Top sites
Beijing 9 Guangzhou 6 Harbin 3 Shanghai 3 Suzhou 3
Narrow the registerReset
Recruitment status
Phase
Site location
Beijing9 Guangzhou6 Harbin3 Shanghai3 Suzhou3
All 25 locations
Target enrolment
to

B Cell Lymphoma trials in China

19 of 19187 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Recruiting
Phase I Study of FXS0683 in the Treatment of Blood Tumors
NCT07616089B-Cell Lymphoma, Acute Myeloid Leukemia, Myelodysplastic Syndromes, Acute Lymphoblastic Leukemia
Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
Phase 1
228
Tianjin
2026-06-02
Recruiting
Chinese PLA General Hospital
Phase 1
18
Beijing
2026-06-01
Recruiting
Anti CD19 Gene Therapy for B-cell Lymphoma
NCT07211048B-cell Lymphoma
Anhui Provincial Hospital
Not applicable
18
Hefei
2026-03-20
Recruiting
Jiangsu Topcel-KH Pharmaceutical Co., Ltd.
Phase 1
30
Suzhou
2026-01-01
Recruiting
The First Affiliated Hospital of Soochow University
Phase 4
40
Suzhou
2025-11-01
Active, closed
Long-Term Safety of Pirtobrutinib in Participants With Previously Treated Types of Blood Cancers
NCT07162181Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell, B-cell Lymphoma
Eli Lilly and Company
Phase 2
13
Beijing, Guangzhou, Harbin, Shanghai, Tianjin, Wuhan
2025-08-07
Recruiting
Chinese PLA General Hospital
Phase 1/2
30
Beijing
2025-06-20
Recruiting
YANRU WANG
Early Phase 1
21
Zhenjiang
2025-05-06
Recruiting
Shanghai Tongji Hospital, Tongji University School of Medicine
Phase 1/2
50
Shanghai
2025-04-22
Recruiting
BeOne Medicines
Phase 3
300
Beijing, Chongqing, Guangzhou, Harbin, Zhengzhou, Wuhan, Nanjing, Xuzhou
2025-03-05
Recruiting
Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd
Phase 1
30
Shanghai
2025-01-23
Recruiting
Safety and Efficacy of Fourth-Generation CAR-T in the Treatment of Hematologic Malignancies
NCT06758713Multiple Myeloma, B-cell Lymphoma, Hematological Malignancy
DrugCar-T
The Third Affiliated Hospital of Southern Medical University
Phase 1
60
Guangzhou
2025-01-15
Recruiting
A Study of XS-04 in Patients With Relapsed or Refractory Hematologic Malignancies
NCT06820268B-cell Lymphoma, Acute Myeloid Leukemia, Myelodysplastic Syndrome
Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
Phase 1
168
Beijing, Guangdong, Hebei, Hubei
2025-01-14
Recruiting
BeOne Medicines
Phase 1/2
80
Fuzhou, Guangzhou, Suzhou, Hangzhou, Wenzhou
2024-11-27
Recruiting
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 2
80
Beijing, Lanzhou, Guangzhou, Guigang, Nanning, Harbin, Anyang, Puyang
2024-11-06
Recruiting
Efficacy and Safety of CD19-CAR.p40-T in Patients With Relapsed/Refractory CD19-Positive Hematologic Malignancies
NCT07584889B Cell Lymphoma, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia
Shenzhen University General Hospital
Phase 1/2
10
Shenzhen
2024-04-20
Recruiting
Chongqing Precision Biotech Co., Ltd
Phase 1
24
Beijing
2023-12-31
Recruiting
CD19/CD22 Bispecific CAR-T Cell Therapy for Relapsed/Refractory B-cell Lymphoma or Acute Lymphoblastic Leukemia
NCT06081478B-cell Acute Lymphoblastic Leukemia, B-cell Lymphoma, Diffuse Large B Cell Lymphoma
Beijing Tongren Hospital
Phase 2
100
Beijing
2022-01-18
Recruiting
Guangzhou Lupeng Pharmaceutical Company LTD.
Phase 1
200
Beijing, Guangzhou
2021-07-06
Rows per page Showing 1–19 of 19
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 9 November 2026. https://priyalifescience.com/clinical-trials-china/condition/b-cell-lymphoma

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,187 studies in total at the last sync on 09 Nov 2026, 03:17 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 19 of those studies listing the condition B Cell Lymphoma.

How many B Cell Lymphoma trials are recruiting in China?

18 of the 19 studies on this page are recruiting new participants as of the 09 Nov 2026, 03:17 UTC sync. A further 0 have not yet opened recruitment, 1 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (B Cell Lymphoma), 19 studies
PhaseStudiesRecruitingShare
Phase 18842.1%
Phase 1/24421.1%
Phase 23215.8%
Early Phase 1115.3%
Not applicable115.3%
Phase 3115.3%
Phase 4115.3%

Most active sponsors

Lead sponsors with the most studies (B Cell Lymphoma)
Lead sponsorStudiesRecruiting
BeOne Medicines22
Chinese PLA General Hospital22
Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.22
Anhui Provincial Hospital11
Beijing Tongren Hospital11
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.11
Chongqing Precision Biotech Co., Ltd11
Eli Lilly and Company10
Guangzhou Lupeng Pharmaceutical Company LTD.11
Jiangsu Topcel-KH Pharmaceutical Co., Ltd.11
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.